Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 3/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4123134 | 0.99 | TSHR (0.43) | TSHRLMNAKAT2BL3MBTL1ALOX15 | |
| SCHEMBL853682 | 0.85 | GSK3B (0.42) | TSHRL3MBTL1ALOX15KMT2AALDH1A1 | |
| SCHEMBL8381615 | 0.85 | SMN1; SMN2 (0.38) | TSHRKAT2BALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL4133179 | 0.84 | GSK3A (0.41) | TSHRLMNAL3MBTL1ALOX15KMT2A | |
| SCHEMBL26097101 | 0.80 | TSHR (0.54) | TSHRLMNAKAT2BL3MBTL1KMT2A | |
| SCHEMBL7068440 | 0.80 | KAT2B (0.43) | TSHRLMNAKAT2BL3MBTL1ALOX15 | |
| SCHEMBL8384325 | 0.79 | GAA (0.44) | LMNAL3MBTL1KMT2AALDH1A1FKBP1A | |
| SCHEMBL5452980 | 0.78 | KDM4E (0.38) | TSHRL3MBTL1ALOX15KMT2AALDH1A1 | |
| SCHEMBL15522924 | 0.78 | NOTUM (0.50) | L3MBTL1KMT2AALDH1A1POLB | |
| SCHEMBL10648648 | 0.77 | KMT2A (0.48) | TSHRLMNAKAT2BL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889835-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| CN-1886376-A | Pyridine compounds as dipeptidyl dipeptidase-IV inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| EP-1224186-B1 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | MILLENNIUM PHARM INC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | disclosed |
| US-6455529-B1 | OXAZOLIDIN-2-ONE DERIVATIVES; ANTICOAGULANTS; ANTIMETASTASIS, ANTICARCINOGENIC, ANTIISCHEMIC, AND ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS, ARTERIOSCLEROSIS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-09-24 | — | — | US | disclosed |
| EP-1224186-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001030780-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| CN-1056141-C | Piperazine derivatives | MERCK PATENT GESELLSCHAFTR MIT (DE) | 2000-09-06 | — | — | CN | disclosed |
| CN-1052231-C | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 2000-05-10 | — | — | CN | disclosed |
| EP-0623615-B1 | Substituted 1-phenyl-oxazolidin-2-one derivatives, their preparation and their use as adhesion-receptor antagonists | MERCK PATENT GMBH (DE) | 1999-06-30 | — | — | EP | disclosed |
| US-5908843-A | Piperazine compounds as fibrinogen inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-06-01 | — | — | US | disclosed |
| EP-0741133-A2 | Adhesion receptor antagonists | MERCK PATENT GmbH (DE) | 1996-11-06 | — | — | EP | disclosed |
| US-5532255-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0623615-A1 | Adhesion-receptor antagonists | MERCK PATENT GmbH (DE) | 1994-11-09 | — | — | EP | disclosed |
| EP-0608759-A2 | Piperazinderivatives | MERCK PATENT GmbH (DE) | 1994-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, FGB | TSHR 1147/4885LMNA 2449/4885KAT2B 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.